Serological differentiation between COVID-19 and SARS infections.


Journal

Emerging microbes & infections
ISSN: 2222-1751
Titre abrégé: Emerg Microbes Infect
Pays: United States
ID NLM: 101594885

Informations de publication

Date de publication:
Dec 2020
Historique:
pubmed: 13 6 2020
medline: 14 7 2020
entrez: 13 6 2020
Statut: ppublish

Résumé

In response to the coronavirus disease 2019 (COVID-19) outbreak, caused by SARS-CoV-2, multiple diagnostic tests are required for acute disease diagnosis, contact tracing, monitoring asymptomatic infection rates and assessing herd immunity. While PCR remains the frontline test of choice in the acute diagnostic setting, serological tests are urgently needed. Unlike PCR tests which are highly specific, cross-reactivity is a major challenge for COVID-19 antibody tests considering there are six other coronaviruses known to infect humans. SARS-CoV is genetically related to SARS-CoV-2 sharing approximately 80% sequence identity and both belong to the species

Identifiants

pubmed: 32529906
doi: 10.1080/22221751.2020.1780951
pmc: PMC7473126
doi:

Substances chimiques

Antibodies, Viral 0
Coronavirus Nucleocapsid Proteins 0
Nucleocapsid Proteins 0
Phosphoproteins 0
Spike Glycoprotein, Coronavirus 0
nucleocapsid phosphoprotein, SARS-CoV-2 0
spike protein, SARS-CoV-2 0

Types de publication

Clinical Trial Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1497-1505

Références

Emerg Infect Dis. 1996 Jul-Sep;2(3):239-40
pubmed: 8903239
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Science. 2003 Oct 10;302(5643):276-8
pubmed: 12958366
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
FEMS Microbiol Rev. 2006 Sep;30(5):760-73
pubmed: 16911043
Antiviral Res. 2013 Oct;100(1):159-89
pubmed: 23906741
Lancet. 2020 Apr 4;395(10230):1101-1102
pubmed: 32247384
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
Emerg Infect Dis. 2003 Jun;9(6):713-7
pubmed: 12781012
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet Infect Dis. 2013 Oct;13(10):859-66
pubmed: 23933067
J Vis Exp. 2009 Oct 07;(32):
pubmed: 19812534
J Immunol Methods. 2000 Sep 21;243(1-2):243-55
pubmed: 10986418
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Emerg Infect Dis. 2014 Apr;20(4):552-9
pubmed: 24655412
J Clin Microbiol. 2006 Jun;44(6):2063-71
pubmed: 16757599
Nature. 2018 Apr;556(7700):255-258
pubmed: 29618817
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Expert Rev Vaccines. 2010 Jun;9(6):567-78
pubmed: 20518713
Emerg Infect Dis. 2004 Dec;10(12):2244-8
pubmed: 15663874
Virology. 1992 Jan;186(1):318-23
pubmed: 1727608
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Clin Diagn Lab Immunol. 2004 Mar;11(2):287-91
pubmed: 15013977
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
J Clin Virol. 2003 Dec;28(3):245-7
pubmed: 14522062
Immunol Lett. 2009 Aug 15;125(2):79-85
pubmed: 19539648
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Science. 2005 Oct 28;310(5748):676-9
pubmed: 16195424
Syst Biol. 2010 May;59(3):307-21
pubmed: 20525638

Auteurs

Wan Ni Chia (WN)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Chee Wah Tan (CW)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Randy Foo (R)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Adrian Eng Zheng Kang (AEZ)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Yilong Peng (Y)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Velraj Sivalingam (V)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Charles Tiu (C)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Xin Mei Ong (XM)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Feng Zhu (F)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Barnaby E Young (BE)

National Centre for Infectious Diseases, Singapore, Singapore.
Tan Tock Seng Hospital, Singapore, Singapore.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.

Mark I-C Chen (MI)

National Centre for Infectious Diseases, Singapore, Singapore.
Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.

Yee-Joo Tan (YJ)

Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, Singapore, Singapore.
Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), Singapore, Singapore.

David C Lye (DC)

National Centre for Infectious Diseases, Singapore, Singapore.
Tan Tock Seng Hospital, Singapore, Singapore.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Danielle E Anderson (DE)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Lin-Fa Wang (LF)

Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH